SOUTH SAN FRANCISCO, Calif.,
Nov. 10, 2020 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced
that Raul Rodriguez, the company's
president and chief executive officer, is scheduled to present a
company overview at the Jefferies Virtual London Healthcare
Conference on Tuesday, November 17,
2020 at 12:00 p.m. Eastern
Time.
To access the live and subsequently archived webcast, go to the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website several minutes
prior to the start of the live webcast to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous
treatment. The product has been approved by the European
Commission for the treatment of chronic immune thrombocytopenia in
adult patients who are refractory to other treatments and is
marketed in Europe under the name
TAVLESSE® (fostamatinib).
Fostamatinib1 is currently being studied in a
Phase 3 trial for the treatment of warm autoimmune hemolytic anemia
(AIHA); a NIH/NHLBI-Sponsored Phase 2 trial for the
treatment of hospitalized COVID-19 patients, in collaboration with
Inova® Health System; and a Phase 2 trial for the
treatment of COVID-19 pneumonia being conducted by Imperial College
London.
Rigel's other clinical programs
include an ongoing Phase 1 study of
R8351, a proprietary molecule from its interleukin
receptor associated kinase (IRAK) inhibitor program, and an
ongoing Phase 1 study of R5521, a proprietary molecule
from its receptor-interacting protein kinase (RIP) inhibitor
program. In addition, Rigel has product candidates in clinical
development with partners AstraZeneca, BerGenBio ASA, and
Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-virtual-london-healthcare-conference-301169278.html
SOURCE Rigel Pharmaceuticals, Inc.